New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
15:33 EDTOMEDOncoMed price target raised to $48 from $38 at Piper Jaffray
Piper Jaffray raised its price target on OncoMed to $48 citing pancreatic cancer data presented at the ASCO-GI symposium.
News For OMED From The Last 14 Days
Check below for free stories on OMED the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2014
18:28 EDTOMEDOn The Fly: After Hours Movers
Subscribe for More Information
16:49 EDTOMEDOncoMed up 6% in after hours trading after FDA lifts partial hold on ipafricept
Subscribe for More Information
16:27 EDTOMEDFDA removes partial clinical hold on OncoMed ipafricept
OncoMed Pharmaceuticals announced that the FDA removed the partial clinical hold on the company's ipafricept phase 1 clinical trials. Enrollment and dosing of new patients is expected to resume within the next few weeks as the study sites' institutional review boards receive and approve the revised trial protocols. Ipafricept is being studied in combination with standard-of-care in three Phase 1b studies. OncoMed submitted a substantial clinical safety and efficacy data package for ipafricept along with revised study protocols to the FDA's Division of Oncology Products 1, which resulted in the removal of the partial clinical hold. The amendments for the phase 1b combination trials include modified dosing regimens, risk mitigation measures, such as increased monitoring and bone protection strategies, and modified enrollment criteria.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use